Bio-Thera Solutions and SteinCares Expand Partnership to Commercialize Dupilumab biosimilar in Latin America
Table of Contents
- Bio-Thera Solutions and SteinCares Expand Partnership to Commercialize Dupilumab biosimilar in Latin America
GUANGZHOU, China and SAN JOSE, Costa Rica – Bio-Thera Solutions, Ltd., and SteinCares announced on June 25, 2025, a new agreement to commercialize a proposed biosimilar of dupilumab across Latin America. This marks the fourth product in their partnership, aimed at providing a cost-effective alternative to one of the world’s top-selling biologics for chronic inflammatory diseases [1].
Strengthening Access to Biosimilars in Latin America
The collaboration reinforces SteinCares’ position as a leading provider of biosimilars in Latin America. Under the agreement, Bio-thera will handle product growth and supply, while SteinCares will manage registration and commercialization throughout the region [1].
Did You Know? The biosimilar market in Latin America is growing, with Brazil leading the way, followed by other countries increasingly adopting biosimilars to reduce healthcare costs [3].
The Role of Dupilumab Biosimilars
Dupilumab, marketed under the brand name Dupixent, is a notable medicine globally in terms of annual sales. The introduction of a biosimilar aims to support the treatment of chronic inflammatory conditions in both adults and children,offering a more affordable option [1].
Executive Perspectives
“Expanding access to advanced therapies while making healthcare more affordable is central to our mission,” said Mitchell Waserstein,CEO of SteinCares. “Through this collaboration, we are reinforcing our position as one of the region’s most robust biosimilar platforms in Latin America, offering a broad portfolio and pipeline tailored to the needs of patients and health systems across the region” [1].
“This collaboration underscores our continued trust in SteinCares as a regional partner with strong regulatory, commercial, and medical capabilities,” said Dr. Shengfeng Li, CEO of Bio-Thera Solutions. “By leveraging steincares’ well-established commercial network, we aim to accelerate the delivery of safe, high-quality, and affordable therapies to patients across Latin America” [1].
SteinCares’ Impact in Latin America
With operations in over 30 countries, SteinCares acts as a bridge between global pharmaceutical innovation and Latin America’s healthcare systems. The company focuses on balancing budgets, expanding access, and improving health outcomes for patients in the region [1].
Partnership Timeline
| Date | event |
|---|---|
| June 25, 2025 | New agreement to commercialize dupilumab biosimilar |
| Ongoing | Bio-thera responsible for product development and supply |
| Ongoing | SteinCares leads registration and commercialization |
Pro Tip: Biosimilars offer a cost-effective alternative to original biologics, perhaps reducing healthcare costs and increasing patient access to essential treatments.
About Bio-Thera Solutions,ltd.
Bio-Thera Solutions, Ltd., based in Guangzhou, China, is a global biopharmaceutical company focused on developing novel therapeutics and biosimilars for various diseases, including cancer and autoimmune conditions. The company has multiple candidates in late-stage development and several approved products in China, the US, and the EU [1].
About SteinCares
SteinCares is a leader in commercializing and distributing specialty healthcare products in Latin America, including biosimilars and innovative pharmaceuticals. With over 40 years of experience, SteinCares partners with global pharmaceutical companies to improve healthcare access and outcomes in the region [1].
What impact will this partnership have on healthcare costs in Latin America?
How can patients in Latin America access these biosimilar treatments?
Evergreen Insights: Biosimilars and Healthcare Access
Biosimilars play a crucial role in expanding access to essential medicines, particularly in regions with limited healthcare resources. By offering cost-effective alternatives to original biologics, biosimilars can significantly reduce healthcare costs and improve patient outcomes.The increasing adoption of biosimilars in Latin America reflects a growing recognition of their value in addressing healthcare challenges and promoting equitable access to treatment.
Frequently Asked Questions About Dupilumab Biosimilars
- What is a dupilumab biosimilar?
- A dupilumab biosimilar is a medication that is highly similar to the original dupilumab biologic, offering a cost-effective alternative for treating chronic inflammatory conditions.
- How dose this partnership improve access to healthcare in Latin America?
- The partnership between Bio-Thera Solutions and SteinCares aims to provide more affordable treatment options, making advanced therapies accessible to a broader patient population in Latin America.
- What role does SteinCares play in this agreement?
- SteinCares is responsible for the registration and commercialization of the dupilumab biosimilar throughout Latin America, leveraging its established network and expertise in the region.
- Why are biosimilars crucial for healthcare systems?
- Biosimilars help reduce healthcare costs by offering competitive pricing compared to original biologics, allowing healthcare systems to allocate resources more efficiently.
- What are the potential benefits of using a dupilumab biosimilar?
- Patients can benefit from a more affordable treatment option for chronic inflammatory conditions,while healthcare systems can reduce overall costs without compromising the quality of care.
- How does Bio-Thera Solutions contribute to this partnership?
- bio-thera Solutions is responsible for the product development and supply of the dupilumab biosimilar, ensuring a consistent and reliable source of medication.
